Takako Inoue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takako Inoue has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Yasuhito Tanaka
Department of Virology and Liver Unit Nagoya City University Graduate School of Medical Sciences Nagoya Japan
11 shared publications - Shintaro Yagi
Fujirebio Inc., 51 Komiya-machi, Hachioji, 192-0031, Tokyo, Japan
4 shared publications Katsumi Aoyagi
3 shared publications- Kentaro Matsuura
Department of Gastroenterology and Metabolism Nagoya City University Graduate School of Medical Sciences Nagoya Japan
3 shared publications Takanori Suzuki
3 shared publications- Atsushi Nakamura
Division of Infection Prevention and Control, Nagoya City University Hospital, Aichi, Japan
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in Hepatology Research
Trends in the Proportion of Hepatitis C Virus Antibody‐Positive Patients Who Could be Considered for Direct‐Acting Antiviral Therapy Identified Through Preoperative Testing for Ophthalmic Surgery: A Nationwide Multicenter Real‐World Cohort Study in Japan
Background and Aims: Although the widespread use of direct‐acting antivirals (DAAs) has reduced the proportion of hepatitis C virus (HCV) antibody‐positive patients eligible for antiviral treatment, the current proportion requiring referral for DAA therapy in ophthalmology departments, which have both high testing volumes and high HCV antibody‐positive rates, remains unclear. Methods: This nationwide multicenter retrospective cohort study included HCV antibody‐positive patients identified through testing in ophthalmology departments at 20 institutions in Japan between 2019 and 2023. The proportions of patients requiring referral for DAA therapy were assessed by electronic medical record (EMR) review across all 20 institutions and by a combination of EMR review and HCV antibody titer determination across nine institutions where antibody titers could be measured. Results: A total of 2792 HCV antibody‐positive patients were identified across 20 institutions. Based on EMR review, the proportions requiring referral for DAA therapy were 44.4%, 38.7%, 34.2%, 38.9%, and 42.5% in 2019, 2020, 2021, 2022, and 2023, respectively. Among 1255 HCV antibody‐positive patients from 9 institutions where HCV antibody titers could be determined, the corresponding proportions assessed by combined EMR review and antibody titer determination were 28.4%, 23.7%, 20.8%, 22.4%, and 25.9%, respectively. Despite a decline in HCV antibody‐positive rates over time, the proportion requiring referral remained high. Conclusions: Although the number of HCV antibody‐positive patients in ophthalmology departments has decreased, a considerable proportion could still be considered for DAA therapy. Combining HCV antibody titer determination with EMR review improves the efficiency of identifying patients requiring referral.
- 16 September 2026
- Published by Wiley in Hepatology Research
Open AccessTrends in the Proportion of Hepatitis C Virus Antibody‐Positive Patients Who Could be Considered for Direct‐Acting Antiviral Therapy Identified Through Preoperative Testing for Ophthalmic Surgery: A Nationwide Multicenter Real‐World Cohort Study in Japan
Background and Aims: Although the widespread use of direct‐acting antivirals (DAAs) has reduced the proportion of hepatitis C virus (HCV) antibody‐positive patients eligible for antiviral treatment, the current proportion requiring referral for DAA therapy in ophthalmology departments, which have both high testing volumes and high HCV antibody‐positive rates, remains unclear. Methods: This nationwide multicenter retrospective cohort study included HCV antibody‐positive patients identified through testing in ophthalmology departments at 20 institutions in Japan between 2019 and 2023. The proportions of patients requiring referral for DAA therapy were assessed by electronic medical record (EMR) review across all 20 institutions and by a combination of EMR review and HCV antibody titer determination across nine institutions where antibody titers could be measured. Results: A total of 2792 HCV antibody‐positive patients were identified across 20 institutions. Based on EMR review, the proportions requiring referral for DAA therapy were 44.4%, 38.7%, 34.2%, 38.9%, and 42.5% in 2019, 2020, 2021, 2022, and 2023, respectively. Among 1255 HCV antibody‐positive patients from 9 institutions where HCV antibody titers could be determined, the corresponding proportions assessed by combined EMR review and antibody titer determination were 28.4%, 23.7%, 20.8%, 22.4%, and 25.9%, respectively. Despite a decline in HCV antibody‐positive rates over time, the proportion requiring referral remained high. Conclusions: Although the number of HCV antibody‐positive patients in ophthalmology departments has decreased, a considerable proportion could still be considered for DAA therapy. Combining HCV antibody titer determination with EMR review improves the efficiency of identifying patients requiring referral.
- 1 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (8) , 103025
Clinical characteristics of Providencia rettgeri bacteraemia and antimicrobial susceptibility patterns
- 1 July 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (8) , 103025
Clinical characteristics of Providencia rettgeri bacteraemia and antimicrobial susceptibility patterns
- Open Access
- 11 March 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (3) , e0146525
Correction for Suzuki et al., “Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversion”
- 11 March 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (3) , e0146525
Open AccessCorrection for Suzuki et al., “Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversion”
- Open Access
- 19 August 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (9) , e0038525
Evaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversion
To assess the performance and clinical relevance of three assays—hepatitis B core-related antigen (HBcrAg), hepatitis B core antigen (HBcAg), and phosphorylated HBcAg (pHBcAg)—in quantifying HBcrAg, a critical biomarker of hepatitis B virus (HBV) infection, fully automated chemiluminescent enzyme immunoassays (CLEIA) for two HBcAg variants were developed. Cutoff values for HBcAg and pHBcAg assays were established at 2.50 and 2.10 LogU/mL, respectively. The strong correlations among components ( r = 0.896–0.970) were observed by using purchased 100 plasma samples. When the dynamics of HBcrAg components were analyzed by using a series of hepatitis B e antigen (HBeAg) seroconversion panel, alongside correlations with HBV markers, distinct dynamics and molecular profiles were observed. For the assessment of the clinical relevance of these assays, serum samples were obtained from 102 HBV-infected patients treated with nucleos(t)ide analog (NA). Both HBcAg and pHBcAg levels were significantly reduced during NA therapy, but in different patterns, suggesting HBV activity independent of HBV DNA and persistent HBcrAg components derived from pc-mRNA. OptiPrep density gradient ultracentrifugation analysis identified pHBcAg as the dominant component in high-density fractions. Immunoprecipitation and Western blotting confirmed that HBcAg components were predominantly enveloped by hepatitis B surface antigen (HBsAg), with pHBcAg identified as the major component of empty viral particles. Although the limitation in sample size in this study, the revealed distinct dynamics of HBcAg, pHBcAg, and HBcrAg during seroconversion and treatment suggest these assays could serve as independent biomarkers for monitoring intrahepatic HBV activity and treatment efficacy. IMPORTANCE: This study evaluates novel fully automated chemiluminescent enzyme immunoassay (CLEIA) systems for hepatitis B core antigen (HBcAg) and phosphorylated HBcAg (pHBcAg) and identifies pHBcAg as the predominant component of hepatitis B virus (HBV)-derived empty viral particles, challenging previous assumptions and providing new insights into HBV biomarkers. HBcAg and pHBcAg show distinct dynamics in hepatitis B e seroconversion and nucleos(t)ide treatment from the other biomarkers including hepatitis B core-related antigen (HBcrAg), HBV RNA, and HBV DNA. The developed CLEIA systems for HBcAg and pHBcAg show promise as tools for monitoring intrahepatic HBV activity, immune clearance, and noninfectious viral replication. Incorporating these biomarkers into clinical practice could refine HBV management strategies, improve reactivation risk prediction, and advance precision medicine approaches.
- 19 August 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (9) , e0038525
Open AccessEvaluation of fully automated chemiluminescent enzyme immunoassays for hepatitis B core-related antigen components, phosphorylated and non-phosphorylated hepatitis B core antigens: clinical significance and dynamics during hepatitis B e antigen seroconversion
To assess the performance and clinical relevance of three assays—hepatitis B core-related antigen (HBcrAg), hepatitis B core antigen (HBcAg), and phosphorylated HBcAg (pHBcAg)—in quantifying HBcrAg, a critical biomarker of hepatitis B virus (HBV) infection, fully automated chemiluminescent enzyme immunoassays (CLEIA) for two HBcAg variants were developed. Cutoff values for HBcAg and pHBcAg assays were established at 2.50 and 2.10 LogU/mL, respectively. The strong correlations among components ( r = 0.896–0.970) were observed by using purchased 100 plasma samples. When the dynamics of HBcrAg components were analyzed by using a series of hepatitis B e antigen (HBeAg) seroconversion panel, alongside correlations with HBV markers, distinct dynamics and molecular profiles were observed. For the assessment of the clinical relevance of these assays, serum samples were obtained from 102 HBV-infected patients treated with nucleos(t)ide analog (NA). Both HBcAg and pHBcAg levels were significantly reduced during NA therapy, but in different patterns, suggesting HBV activity independent of HBV DNA and persistent HBcrAg components derived from pc-mRNA. OptiPrep density gradient ultracentrifugation analysis identified pHBcAg as the dominant component in high-density fractions. Immunoprecipitation and Western blotting confirmed that HBcAg components were predominantly enveloped by hepatitis B surface antigen (HBsAg), with pHBcAg identified as the major component of empty viral particles. Although the limitation in sample size in this study, the revealed distinct dynamics of HBcAg, pHBcAg, and HBcrAg during seroconversion and treatment suggest these assays could serve as independent biomarkers for monitoring intrahepatic HBV activity and treatment efficacy. IMPORTANCE: This study evaluates novel fully automated chemiluminescent enzyme immunoassay (CLEIA) systems for hepatitis B core antigen (HBcAg) and phosphorylated HBcAg (pHBcAg) and identifies pHBcAg as the predominant component of hepatitis B virus (HBV)-derived empty viral particles, challenging previous assumptions and providing new insights into HBV biomarkers. HBcAg and pHBcAg show distinct dynamics in hepatitis B e seroconversion and nucleos(t)ide treatment from the other biomarkers including hepatitis B core-related antigen (HBcrAg), HBV RNA, and HBV DNA. The developed CLEIA systems for HBcAg and pHBcAg show promise as tools for monitoring intrahepatic HBV activity, immune clearance, and noninfectious viral replication. Incorporating these biomarkers into clinical practice could refine HBV management strategies, improve reactivation risk prediction, and advance precision medicine approaches.
- Open Access
- 1 April 2025
- Published by Japan Society of Hepatology in Kanzo
- Vol. 66 (4) , 156-158
Effectiveness of Hepatitis Medical Care Coordinator Certification for Dentists: An Aichi Dental Association Initiative
- 1 April 2025
- Published by Japan Society of Hepatology in Kanzo
- Vol. 66 (4) , 156-158
Open AccessEffectiveness of Hepatitis Medical Care Coordinator Certification for Dentists: An Aichi Dental Association Initiative
- 8 August 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (1) , 102492
Multicenter surveillance of the outcomes of and antimicrobial susceptibility to acute cystitis caused by Staphylococcus saprophyticus
- 8 August 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (1) , 102492
Multicenter surveillance of the outcomes of and antimicrobial susceptibility to acute cystitis caused by Staphylococcus saprophyticus
- Open Access
Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening
Hepatitis B core-related antigen (HBcrAg) reflects the activity of intrahepatic covalently closed circular DNA. HBcrAg can be detected even in chronic hepatitis B patients in whom serum HBV DNA or hepatitis B surface antigen is undetectable. The HBcrAg measurement system was developed based on two concepts. One is a fully-automated and highly-sensitive HBcrAg assay (iTACT-HBcrAg) and the other is a point-of-care testing (POCT) that can be used in in resource-limited areas. iTACT-HBcrAg is an alternative to HBV DNA for monitoring HBV reactivation and predicting the development of hepatocellular carcinoma. This validated biomarker is available in routine clinical practice in Japan. Currently, international guidelines for the prevention of mother-to-child transmission recommend anti-HBV prophylaxis for pregnant women with high viral loads. However, over 95% of HBV-infected individuals live in countries where HBV DNA quantification is widely unavailable. Given this situation, a rapid and simple HBcrAg assay for POCT would be highly effective. Long-term anti-HBV therapy may have potential side effects and appropriate treatment should be provided to eligible patients. Therefore, a simple method of determining the indication for anti-HBV treatment would be ideal. This review provides up-to-date information regarding the clinical value of HBcrAg in HBV management, based on iTACT-HBcrAg or POCT.
Open AccessTwo Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening
Hepatitis B core-related antigen (HBcrAg) reflects the activity of intrahepatic covalently closed circular DNA. HBcrAg can be detected even in chronic hepatitis B patients in whom serum HBV DNA or hepatitis B surface antigen is undetectable. The HBcrAg measurement system was developed based on two concepts. One is a fully-automated and highly-sensitive HBcrAg assay (iTACT-HBcrAg) and the other is a point-of-care testing (POCT) that can be used in in resource-limited areas. iTACT-HBcrAg is an alternative to HBV DNA for monitoring HBV reactivation and predicting the development of hepatocellular carcinoma. This validated biomarker is available in routine clinical practice in Japan. Currently, international guidelines for the prevention of mother-to-child transmission recommend anti-HBV prophylaxis for pregnant women with high viral loads. However, over 95% of HBV-infected individuals live in countries where HBV DNA quantification is widely unavailable. Given this situation, a rapid and simple HBcrAg assay for POCT would be highly effective. Long-term anti-HBV therapy may have potential side effects and appropriate treatment should be provided to eligible patients. Therefore, a simple method of determining the indication for anti-HBV treatment would be ideal. This review provides up-to-date information regarding the clinical value of HBcrAg in HBV management, based on iTACT-HBcrAg or POCT.
- Open Access
- 1 March 2023
- Published by Japan Society of Hepatology in Kanzo
- Vol. 64 (3) , 150-151
Problems regarding the hepatitis B vaccination status of Japanese dentists
We conducted surveys to assess the hepatitis B (HB) vaccination status of dentists. From 2020 to 2022, 1,033 members of dental associations in Aichi and Hiroshima prefectures were questioned regarding their HB vaccination status. The respondents were determined to have been properly vaccinated if they had received three or more doses of vaccine or had been vaccinated but their hepatitis B surface antibody titers had not increased. Of the respondents, 20.6% (213/1,033) had undergone appropriate vaccination, 34.8% (360/1,033) were unvaccinated, and 42.8% (442/1,033) had received two doses. In dentistry, there are several opportunities for exposure to saliva and blood and needlestick accidents may occur. Dental professionals will be made aware of the HB immunization schedule using precise infection control procedures.
- 1 March 2023
- Published by Japan Society of Hepatology in Kanzo
- Vol. 64 (3) , 150-151
Open AccessProblems regarding the hepatitis B vaccination status of Japanese dentists
We conducted surveys to assess the hepatitis B (HB) vaccination status of dentists. From 2020 to 2022, 1,033 members of dental associations in Aichi and Hiroshima prefectures were questioned regarding their HB vaccination status. The respondents were determined to have been properly vaccinated if they had received three or more doses of vaccine or had been vaccinated but their hepatitis B surface antibody titers had not increased. Of the respondents, 20.6% (213/1,033) had undergone appropriate vaccination, 34.8% (360/1,033) were unvaccinated, and 42.8% (442/1,033) had received two doses. In dentistry, there are several opportunities for exposure to saliva and blood and needlestick accidents may occur. Dental professionals will be made aware of the HB immunization schedule using precise infection control procedures.
- Open Access
- 2 October 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (10) , 2083
Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B
The hepatitis B core-related antigen (HBcrAg) is an unprecedented novel HBV biomarker that plays an essential role in reflecting covalently closed circular DNA (cccDNA) in chronic hepatitis B (CHB) because its levels correlate with intrahepatic cccDNA and serum HBV DNA. In this review, we describe the clinical application of serum HBcrAg in CHB patients, with a particular focus on new therapies targeting intrahepatic HBV replication. (1) HBcrAg can be detected in clinical cases where serum HBV DNA is undetectable during anti-HBV therapy. (2) A highly sensitive HBcrAg assay (iTACT-HBcrAg) may be useful for monitoring HBV reactivation, as an alternative to HBV DNA. (3) Decreased HBcrAg levels have been significantly associated with promising outcomes in CHB patients, reducing the risk of progression or recurrence of hepatocellular carcinoma. Additionally, we focus on and discuss several drugs in development that target HBV replication, and monitoring HBcrAg may be useful for determining the therapeutic efficacies of such novel drugs. In conclusion, HBcrAg, especially when measured by the recently developed iTACT-HBcrAg assay, may be the most appropriate surrogate marker, over other HBV biomarkers, to predict disease progression and treatment response in CHB patients.
- 2 October 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (10) , 2083
Open AccessHepatitis B Core-Related Antigen and New Therapies for Hepatitis B
The hepatitis B core-related antigen (HBcrAg) is an unprecedented novel HBV biomarker that plays an essential role in reflecting covalently closed circular DNA (cccDNA) in chronic hepatitis B (CHB) because its levels correlate with intrahepatic cccDNA and serum HBV DNA. In this review, we describe the clinical application of serum HBcrAg in CHB patients, with a particular focus on new therapies targeting intrahepatic HBV replication. (1) HBcrAg can be detected in clinical cases where serum HBV DNA is undetectable during anti-HBV therapy. (2) A highly sensitive HBcrAg assay (iTACT-HBcrAg) may be useful for monitoring HBV reactivation, as an alternative to HBV DNA. (3) Decreased HBcrAg levels have been significantly associated with promising outcomes in CHB patients, reducing the risk of progression or recurrence of hepatocellular carcinoma. Additionally, we focus on and discuss several drugs in development that target HBV replication, and monitoring HBcrAg may be useful for determining the therapeutic efficacies of such novel drugs. In conclusion, HBcrAg, especially when measured by the recently developed iTACT-HBcrAg assay, may be the most appropriate surrogate marker, over other HBV biomarkers, to predict disease progression and treatment response in CHB patients.